Police said they had busted a network that saw smugglers swim on the high seas to help stash Colombian cocaine on container ships and hijack vessels.

A new Science paper links the sharp decline in U.S. overdose deaths since 2023 to reduced fentanyl potency, pointing to a supply-side shock.

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns, including the death of a patient while taking one of the medicines,

TrumpRx is supposed to launch in early 2026. Here's what we know about how buying medicine through the site to get discounts on prescription drugs will work

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for hospital formularies,

The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the agency, stoking worries that the plan may run afoul of legal,

Cartel Expert Becomes First Woman to Lead Nation’s Drug Control Policy Today, in a 52-48 vote, United States Senate confirmed Sara Carter as the 10th

President Donald Trump said he plans to eliminate pharmacy benefit manager kickbacks to lower drug prices and insurance premiums for Americans under his new healthcare plan.

On July 2, the U.S. Food and Drug Administration (FDA) approved a new drug for treating Alzheimer’s disease. Donanemab, or Kisunla, is the third drug approved to target one of the causes of Alzheimer’s: the buildup of amyloid protein in the brain.

The Shelby County Drug Enforcement Task Force released their 2025 arrest data on Wednesday, Jan. 14. According to the data, the force issued more than 700 arrest warrants and took 318 people into custody. They also reportedly seized over 46 pounds of illegal drugs.

A plan to slash drug review times at the Food and Drug Administration is sparking deep concerns among agency staffers and outside experts, with some saying the poorly defined effort is taking key decisions away from career scientists and placing them in the hands of political leadership.